Assay Report
Methods · Standard Curves · QC · Results
Comprehensive single-molecule digital immunoassay services for quantifying Total Tau (t-Tau), brain-derived tau (BD-Tau), and key phosphorylated tau isoforms (p-Tau181, p-Tau231, and p-Tau217) in plasma, serum, CSF, and tissue lysates down to sub-picogram per milliliter detection limits.
Mapping the progressive phosphorylation cascade of tau is central to staging preclinical Alzheimer's pathology, differentiating primary tauopathies, and evaluating anti-tau drug candidates. Creative Proteomics delivers customized multi-epitope sampling frameworks and high-precision research datasets for translational neuroscience pipelines.
Aligning biological milestones, epitope dynamics, and analytical controls for neurodegeneration pipelines.
Translating biofluid tau measurements into conclusive therapeutic insights requires matching the specific phospho-epitope to the underlying pathological stage. Creative Proteomics establishes five universal design dimensions prior to testing:
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Target Epitope Staging | Incipient seeding (p231), amyloid plaque surge (p217/p181), or structural loss (t-Tau / BD-Tau) | Selects the precise biomarker sensitive to your drug candidate's mechanism of action. |
| Baseline & Vehicle Controls | Pre-dose intra-individual baselines vs. age-matched parallel non-transgenic wild-type cohorts | Isolates true drug-induced tau reduction from progressive age-associated accumulation. |
| Multi-Marker Alignment | Combining phospho-tau with structural markers (Simoa NfL) and astrogliosis (glial fibrillary acidic protein [GFAP]) | Builds an integrated ATN (Amyloid, Tau, Neurodegeneration) profile from a single sample aliquot. |
| Analytical Volume Allocation | Serial micro-volume allocation (15 μL net), duplicate confirmation, and orthogonal follow-up reserve | Preserves longitudinal small-animal biofluids (e.g., serial submandibular bleeds) across multi-month studies. |
| Plate Balancing & Randomization | Balancing vehicle, candidate drug doses, and longitudinal timepoints across analytical disc runs | Eliminates confounding between true experimental treatment effects and run-to-run assay variance. |
Evaluating clinical utility, dynamic fold-induction, and optimal study staging across our single-molecule tau assay portfolio.
| Target Analyte | Pathological Horizon | Relative Blood Signal | Recommended Preclinical Study Application |
|---|---|---|---|
| Phospho-Tau 231 (p-Tau231) | Incipient A oligomer seeding; earliest conformational shift | 1.8–3.5× elevation | Ultra-early pre-symptomatic animal cohort stratification; prevention trials |
| Phospho-Tau 217 (p-Tau217) | Active cortical amyloid plaque & tangle progression | 4.0–8.0× elevation (Highest dynamic range) | IND candidate efficacy tracking; primary pharmacodynamic surrogate for amyloid-tau |
| Phospho-Tau 181 (p-Tau181) | Intermediate amyloidosis & tau hyperphosphorylation | 1.5–3.0× elevation | Broad cohort baseline profiling; legacy clinical trial dataset alignment |
| Brain-Derived Tau (BD-Tau) | CNS-specific neurodegeneration; zero peripheral interference | 1.5–2.5× elevation | Evaluating Alzheimer's-type cortical neurodegeneration without non-brain tau noise |
| Total Tau (t-Tau) | Non-specific acute axonal injury & rapid structural breakdown | 1.2–1.8× elevation | Traumatic brain injury (TBI), stroke models, acute neurotoxicity benchmarking |
Evaluating analytical performance, multi-epitope coverage, and data continuity across bioanalytical platforms for translational neuroscience programs.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | >10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.5 – 2.0 pg/mL | 0.01 – 0.06 pg/mL (fg/mL level) |
| Healthy Blood Basal Detectability | <20% (High dropout rate) | 40% – 60% (Baseline dropout risk) | 60% – 80% (CSF optimal; plasma variable) | 100% Quantifiable across all cohorts |
| Sample Volume Consumption | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Multi-Epitope Multiplexing | Singleplex (1 analyte) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Linear Dynamic Range | 2.0 logs | 3.0 – 3.5 logs | 3.5 – 4.0 logs | >4.5 logs (Poisson digital + Analog) |
| Serial Small Rodent Sampling | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial submandibular/tail bleeds) |
| Primary Matrix Suitability | High-abundance in vitro systems | Systemic multi-target discovery | CSF, post-mortem brain tissue | Peripheral blood (serum/plasma), micro-fluids |
Transitioning historical cohorts from plate ELISA, MSD, Luminex, Lumipulse, or LC-MS/MS to digital Simoa requires formal method bridging. Variations in antibody clone epitopes, synthetic calibrator peptide formulations, and matrix dilution factors commonly introduce proportional numerical shifts, even when inter-platform rank correlations exceed r = 0.95.
Our Bridging Protocol: We test a representative pilot subset (15–20 paired baseline and elevated specimens) across both platforms to establish a formal linear conversion algorithm, ensuring seamless multi-year dataset continuity.
Bioanalytical parameters validated according to FDA Bioanalytical Method Validation (BMV) and International Council for Harmonisation (ICH) M10 guidelines.
Stringent specificity validation confirming zero mutual cross-reactivity between individual antibody pairs targeting Thr231, Thr217, Thr181, and non-phosphorylated Total Tau.
High-resolution spectral separation of fluorescently dye-encoded paramagnetic bead populations with zero optical crosstalk across multiplex single-molecule detection wells.
Analytical verification of derived mathematical ratios (p-Tau217/t-Tau, p-Tau181/t-Tau, p-Tau231/t-Tau) ensuring linear precision across the full dynamic range.
Specimens received on dry ice are barcode-logged, assessed for hemolysis/lipemia, and cataloged into monitored −80 °C storage.
Automated liquid handling performs sample dilution in matrix-matched assay diluent supplemented with selective blockers (HAMA/HAAA).
Target tau proteins are captured onto paramagnetic beads functionalized with high-affinity monoclonal antibodies, followed by detector binding.
Bead-enzyme complexes (SBG) are loaded onto optical Simoa discs with 216,000 femtoliter wells, sealed with oil, and imaged for digital enzyme counting.
Average Enzymes per Bead (AEB) values are fitted against calibration curves to output absolute pg/mL concentrations and QC statistics.
A standardized pre-analytical framework to preserve phospho-epitope integrity and prevent non-biological variance.
| Pre-Analytical Parameter | Why It Matters for Tau / Phospho-Tau Bioanalysis | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Phosphorylated epitopes are sensitive to matrix composition; K2-EDTA yields superior signal-to-noise ratios and stability over heparin. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted consistently for 30–60 min at RT. |
| Centrifugation Timing | Endogenous blood phosphatases can dephosphorylate Thr181/231/217 if whole blood remains uncentrifuged at room temperature. | Centrifuge at 2,000 μg for 15 min at 4 °C within 60 minutes of collection; harvest platelet-poor plasma. |
| Phosphatase Inhibition | Tissue homogenates contain active serine/threonine phosphatases that rapidly degrade p-Tau signals post-lysis. | Include broad-spectrum phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF) in RIPA or Tris lysis buffers. |
| Freeze-Thaw Stability | Tau proteins maintain stability in EDTA plasma, but repeated freeze-thaw cycles (>4 cycles) can increase background. | Aliquot immediately into polypropylene cryovials; store at −80 °C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Micro-volume consumption allows serial longitudinal sampling in precious transgenic rodent cohorts. | 15 μL net volume per well (30 μL recommended to support duplicate verification and analytical reserve). |
| Run Allocation & Balancing | Placing baseline and post-treatment cohorts on separate plates risks confounding treatment effects with batch variance. | We pre-plan plate layouts so that paired longitudinal timepoints and cohort groups are balanced across the same run. |
Accelerating drug candidate evaluation, disease model characterization, and biomarker discovery.
Map the temporal hierarchy of tau pathology from incipient soluble seeding (p231) to active plaque surge (p217) and clinical baseline (p181).
Assess candidate GSK3β, CDK5, or PP2A modulators against multiple phosphorylation residues simultaneously in cellular and animal models.
Distinguish 3R/4R primary tauopathies (FTD, PSP, CBD) from secondary Alzheimer's amyloid-driven tau cascades in preclinical models.
Evaluate monoclonal antibodies, PROTACs, or autophagy inducers targeting paired helical filaments and neurofibrillary tangles.
Analyze central-to-peripheral transport rates and fractional clearance kinetics across multiple phospho-tau species in paired cohorts.
Monitor free versus antibody-complexed tau fractions following systemic administration of therapeutic anti-tau monoclonal antibodies.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies establishing multi-epitope tau profiling across the neurodegenerative continuum.
Study Design Takeaway: Establishes plasma p-Tau181 as a robust clinical biomarker differentiating AD from non-AD tauopathies with high diagnostic precision.
Study Design Takeaway: Demonstrates that plasma p-Tau231 increases in early pre-symptomatic stages before Amyloid-PET threshold positivity, ideal for prevention models.
Study Design Takeaway: Confirms the sequential staging power of p-Tau231 (earliest rise) followed by p-Tau217 (steepest dynamic curve) across disease progression.
Study Design Takeaway: Validates BD-Tau as a brain-specific neurodegeneration marker that correlates with CSF total tau while avoiding non-CNS peripheral tau confounders.
Study Design Takeaway: Demonstrates high sensitivity of blood p-Tau181 across multi-cohort clinical and preclinical paradigms.
Addressing common bioanalytical and project planning inquiries.
Epitope selection depends on your study's pathological horizon: use p-Tau231 for ultra-early pre-symptomatic seeding and prevention paradigms; p-Tau217 for therapeutic efficacy tracking, IND candidates, and tight Amyloid-PET correlation; p-Tau181 for general cohort stratification; and Total Tau / BD-Tau for quantifying acute structural axonal injury and general neurodegeneration.
Conventional Total Tau immunoassays detect both CNS-derived tau and tau produced by peripheral tissues (e.g., salivary glands, liver). BD-Tau utilizes specialized antibody pairings that specifically target brain-expressed tau fragments, completely eliminating peripheral background noise and providing an accurate blood readout of central neurodegeneration.
Yes. With as little as 15–30 μL of net sample volume, our single-molecule Simoa platform can evaluate multiple distinct tau phospho-isoforms or multiplex panels, conserving valuable small-animal biofluids and enabling multi-analyte ratio analysis.
K2-EDTA plasma is strongly recommended for longitudinal animal studies due to high stability and rapid processing without clotting-induced variability. Serum is also fully compatible when processed under uniform 30–60 min clotting SOPs. We recommend maintaining the same collection tube type across all longitudinal study timepoints.
Phosphorylated tau epitopes are susceptible to endogenous phosphatase activity if whole blood remains uncentrifuged at room temperature. We recommend centrifuging blood within 60 minutes of collection at 4 °C and storing plasma aliquots at −80 °C. For tissue homogenates, include a cocktail of broad-spectrum serine/threonine phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF).
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×